What is the Study?
A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer's Disease (Phase 2/3; Protocol No. MK-8931-017-03) (also known as SCH 900931, P07738)
What is the Purpose of MK-8931?
Merck is evaluating the effectiveness and safety of an oral study drug that may help slow the progression of mild to moderate Alzheimer's disease. Study related drugs and care will be provided at no cost. Participation is expected to last up to 20 months, including screening, study drug dosing and follow-up.
Must be 55-85 years old. Have an Alzheimer's disease diagnosis or think you may have Alzheimer's disease. Have symptoms of mental or functional decline dating back at least 1 year and have a study partner or caregiver willing to bring you to study visits and help you follow study requirements.
If you are interested in learning more about the MK-8931 study, please call (401) 455-6403 or send an e-mail to: email@example.com.
For information on other current research studies at Butler Hospital please click here.